Cladribine Treatment Improved Homocysteine Metabolism and Increased Total Serum Antioxidant Activity in Secondary Progressive Multiple Sclerosis Patients

Table 3

Effect of cladribine on serum PON1 activity, level of Hcy, HTL, antibodies against homocysteinylated proteins, and FRAP in SP-MS patients. Results are reported as (SD) with the exception of PON1 activity (shown as median, min-max).

Variable	SP-MS before cladribine	SP-MS after cladribine
PON1 activity (U/ml)	80.3 (35.0-307.1)	78.1 (39.3-290.0)
AE activity (U/ml)
PON1 lactonase activity (U/ml)
Hcy (μM)
HTL (μM)
Antibodies against homocysteinylated proteins (A490)
FRAP (μM)

AE: arylesterase; A490: absorbance measured at 490 nm; FRAP: ferric-reducing ability of plasma; Hcy: homocysteine; HTL: homocysteine thiolactone; MS: multiple sclerosis; PON1: paraoxonase 1; RR-MS: relapsing-remitting type of multiple sclerosis; SP: secondary progressive type of multiple sclerosis; and vs. untreated initial status.